# Targeting C3a and C5a Signaling—A Game Changer for Cancer Therapy?

## TL;DR

This paper explores how proteins C3a and C5a from the complement system help cancer grow and spread, suggesting that blocking them could improve cancer treatments.

## Contribution

The paper systematically reviews how C3a and C5a signaling promotes cancer progression and highlights their potential as therapeutic targets.

## Key findings

- C3a and C5a proteins promote cancer cell growth and spread by weakening the immune system.
- Blocking C3a and C5a signaling pathways can inhibit tumor growth and metastasis.
- C3a and C5a interact with immune cells in the tumor microenvironment to drive cancer progression.

## Abstract

Cancer is one of the deadliest diseases worldwide. When cancer cells spread to other parts of the body, the disease is hard to treat. One of our body’s defense systems, called the complement system, usually fights off infections, but recent studies show that it can also help cancer cells grow and spread. We examined research on two proteins from this system, C3a and C5a, and found that they can make cancer worse. They do this in two ways: directly helping cancer cells grow and multiply, and weakening the immune system’s ability to fight them. This means that C3a and C5a can help cancer cells thrive and spread to other parts of the body. This discovery opens up new possibilities for cancer treatment. One potential solution is to use medicines that inhibit those two proteins, which could help treat cancer more effectively. In conclusion, the complement system’s components, C3a and C5a, play a significant role in promoting cancer cell growth and spread. By understanding their mechanisms, we can explore new approaches to cancer treatment, such as using inhibitors to block their effects. This promising avenue of research holds potential for improving cancer therapy and patient outcomes.

Emerging evidence reveals a significant shift in understanding the complement system’s role in cancer, where activation of a complement within the tumor microenvironment (TME) fuels tumor growth and metastasis instead of suppressing it. Research highlights C3a and C5a anaphylatoxins as key drivers of cancer progression, showing that the blockade of their signaling pathways can inhibit tumor growth and metastasis. By interacting with immune cells in the TME, including tumor-associated macrophages (TAMs), T cells, and myeloid-derived suppressor cells, C3a and C5a promote immunosuppression, thereby driving cancer cell proliferation, angiogenesis, and metastasis. However, conflicting findings persist, despite growing evidence supporting the role of C3a and C5a in tumor progression and the potential therapeutic benefits of targeting pathological complement activation. This paper presents a systematic review of studies examining the activation of the complement system and the role of the C3a and C5a signaling pathways in the TME, focusing on their effects on tumor progression, their interactions with TME components, and the potential for targeting these signaling pathways to boost anti-tumor immune responses.